ERVW-1 and HIV-1 infection: The RV-144 trial, utilizing a recombinant canarypox vector prime vaccine followed by a boost with a recombinant HIV-1 surface protein Env subunit (HIV-1 glycoprotein 120, gp120), showed limited protection against HIV-1 infection that was associated with the generation of anti-Env antibodies binding V1V2 viral regions1.